#Substance-Use

2 stories

Research March 31, 2026 · View digest

Eli Lilly and Baseline Therapeutics Investigate GLP-1s for Substance Use Disorders

Lilly and startup Baseline Therapeutics are investigating GLP-1 RAs for alcohol and substance use disorders. A large VA study found GLP-1s associated with reduced substance abuse risk, in a therapeutic area projected to reach $12.4B by 2033.

Research March 25, 2026 · View digest

Semaglutide Linked to 42% Drop in Psychiatric Hospital Visits

Large-scale study from University of Eastern Finland and Karolinska Institutet found GLP-1 medications associated with 42% drop in psychiatric hospital visits, 44% lower depression risk, and 47% reduced substance use disorders.